BC Technical and UltraSPECT Inc. have entered into a long-term agreement to provide their customers easier access to UltraSPECT products across the nation.
The U.S. Food and Drug Administration (FDA) has completed its safety review and has found no clear evidence of increased cardiovascular risks associated with use of the blood pressure medication olmesartan in diabetic patients.
NYU Langone Medical Center is now using a novel technology that serves as a "flight simulator" for neurosurgeons, allowing them to rehearse complicated brain surgeries before making an actual incision on a patient.
OrbusNeich announced the completion of enrollment in the prospective, multicenter, all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio-Engineered Sirolimus Eluting Stent) Post Market Registry) to evaluate the Combo stent for the treatment of coronary lesions in the setting of routine clinical care.
Researchers have announced the results of a study that used a novel echocardiographic technique to detect and quantify damage to heart muscle even after an episode of mild cardiac injury from ischemia (low blood flow to the heart) has resolved.
If you enjoy this content, please share it with a colleague
Researchers have announced the results of a study that used speckle-tracking echocardiography (STE) to analyze early phase one results from the multi-center COMPASSION trial, which seeks to examine the safety and efficacy of a new option to replace dysfunctional pulmonary valves in a subset of congenital heart disease patients.
June 23, 2014 — Men who reported being sedentary, with low levels of physical activity, were at a significantly higher risk for heart failure than those who were more active, according to a Kaiser Permanente study published earlier this year in the journal Circulation: Heart Failure. The study showed the increased risk of heart failure with prolonged sedentary behavior.
June 23, 2014 — Edwards Lifesciences Corp. announced that three-year clinical outcomes of its Edwards Intuity valve platform demonstrated improved cardiac and valvular performance, as well as patient functional status.
June 23, 2014 — BG Medicine Inc. earlier this year announced the issuance of patent 8,672,857, titled “Galectin-3 and Cardiac Resynchronization Therapy,” by the United State Patent and Trademark Office. The patent claims methods for predicting responsiveness to cardiac resynchronization therapy by the measurement of the concentration of the protein galectin-3 in blood.
